# US 11,299,530 B2 · SIRP alpha-CD70 fusion protein and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,299,530 B2
- Document ID: US11299530B2
- Status: Granted
- Kind: B2
- Application number: 16/475,683
- Filed: 2018-01-04
- Published: 2019-10-17
- Granted: 2022-04-12
- Earliest claimed: 2017-01-05
- Assignees: KAHR Medical Ltd.
- Applicants: KAHR Medical Ltd.
- Inventors: Noam Shani; Yosi Gozlan; Michal Dranitzki Elhalel; Edwin Bremer; Ido Kaminsky
- Web page: https://patentgrep.com/patent/US11299530B2

## CPC

- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- A61P 35/00: Antineoplastic agents
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/21: containing a His-tag
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.

## Claims

### Claim 1

A SIRPα-CD70 fusion protein being characterized by a single amino acid linker between said SIRPα and said CD70; and in a form of at least a homo-trimer, wherein said SIRPα-CD70 fusion protein amino acid sequence comprises SEQ ID NO: 1.

### Claim 2 (depends on 1)

The SIRPα-CD70 fusion protein of claim 1, wherein said at least homo-trimer is at least 140 kD in molecular weight as determined by SDS-PAGE.

### Claim 3 (depends on 1)

The SIRPα-CD70 fusion protein of claim 1, being soluble.

### Claim 4 (depends on 1)

The SIRPα-CD70 fusion protein claim 1, wherein said fusion protein is capable of at least one of:
(i) binding CD47 and CD27;
(ii) activating said CD27 signaling pathway in a cell expressing said CD27;
(iii) co-stimulating immune cells expressing said CD27; and/or
(iv) enhancing phagocytosis of pathologic cells expressing said CD47 by phagocytes compared to same in the absence of said SIRPα-CD70 fusion protein.

### Claim 5 (depends on 1)

The SIRPα-CD70 fusion protein of claim 1, wherein said SIRPα-CD70 fusion protein amino acid sequence consists of SEQ ID NO: 1.

### Claim 6 (depends on 1)

A host cell comprising the SIRPα-CD70 fusion protein of claim 1.

### Claim 7 (depends on 1)

An article of manufacture identified for the treatment of a disease that can benefit from activating immune cells comprising a packaging material packaging a therapeutic agent for treating said disease; and the SIRPα-CD70 fusion protein of claim 1.